Informational Alert

Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

High Priority Alert

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Current Research Studies

Prospective Body Composition Assessment and Correlation to Metabolic Profile in Survivors of Childhood Brain Tumors

SC-N157: Body Composition in Brain Tumor Survivors

  • Condition(s): Atypical Teratoid/Rhabdoid Tumor, Brain Tumor, CNS Embryonal Tumors, CNS Germ Cell Tumors, CNS Sarcoma, Choroid Plexus Tumors, Ependymoma, Glioneuronal and Neuronal Tumors, High-Grade Glioma, Medulloblastoma, Survivorship
  • Phase: N/A
  • Clinicaltrials.gov ID: NCT33333333

What is the goal of the study?

Survivors of childhood brain tumors have unique risk factors for metabolic problems, including obesity, diabetes and cholesterol problems. Some research has shown that there may be blood tests that can show early risk for metabolic problems. The goal of this study is to evaluate the relationship between blood tests for metabolic problems with body composition as measured by a device called the BOD POD. We are doing this research study to answer the following questions: 1. What is the relationship between the BOD POD body composition measurement and different markers of metabolic problems in survivors of childhood brain tumors? 2. Do survivors of childhood brain tumors experience metabolic problems more than people who did not have a childhood brain tumor? 3. Does body composition differ between survivors of childhood brain tumors and people who did not have a childhood brain tumor? 4. How common is it for survivors of childhood brain tumors to have metabolic markers that are different than what we would expect?

Who can participate in the study?

-Survivors of a childhood brain tumor who received treatment that included chemotherapy, radiation therapy, or both. -Diagnosed with a childhood brain tumor at age 21 years or younger. -Currently within 5 years since therapy completion.

Study Team: